QTTB Q32 Bio Inc. Insider Trading

Director Diyong Xu acquired 1,875,000 shares for $15,000,000.00 at $8.00 via 2 transactions in private placement deal

Director Diyong Xu completed two separate purchases totaling 1,875,000 shares for $15,000,000.00 at $8.00 per share on 2026-05-28. The filing is flagged as a private placement, PIPE, registered direct, or IPO allocation—not a discretionary open-market purchase, so this transaction does not reflect independent insider conviction. The current stock price of $11.66 stands 11.3% below the 52-week high of $13.15, and the company reported zero revenue in the latest quarter with net income of -$7,609,000.00. The acquisition is noteworthy as a significant capital commitment ($15.0M) by a director during structured financing, but investors should distinguish this from voluntary open-market accumulation.

Orbimed Advisors LLC (Director) purchases 1,875,000 shares for $15,000,000.00 in private placement at Q32 Bio.

Orbimed Advisors LLC purchased 1,875,000 shares across 2 separate transactions on 2026-05-28, paying $8.00 per share for a total of $15,000,000.00. However, this transaction is flagged as a private placement—not a discretionary open-market purchase—and therefore should not be interpreted as an expression of insider conviction about the stock's near-term prospects. The stock currently trades at $11.66, up 131.4% over 30 days and 138.4% over 90 days, placing it 11.3% below its 52-week high of $13.15. Q32 Bio is an early-stage biotech company with zero quarterly revenue and a net loss of $7,609,000.00, typical for pre-commercial stage enterprises. The private-placement structure indicates this was a structured financing event rather than an open-market vote of confidence, limiting the signal value for momentum or directional conviction.